FTQ Invests $20M in CELYSTRA Pharma to Expand Rare Disease Portfolio
Event summary
- Fonds de solidarité FTQ joins $20M financing round for CELYSTRA Pharma, a Québec-based biopharmaceutical startup launched in May 2026.
- CELYSTRA's first product, olezarsen (TRYNGOLZA®), is approved by Health Canada for familial chylomicronemia syndrome (FCS).
- Company also secured Canadian rights to donidalorsen, a treatment for hereditary angioedema (HAE), currently under Health Canada review.
- FTQ brings $23B in AUM and a track record of impact investing in Québec's life sciences sector.
The big picture
FTQ's investment underscores Québec's growing life sciences sector, with a focus on rare disease therapies. The $20M round positions CELYSTRA to bridge gaps in treatment access for conditions like FCS and HAE, which are more prevalent in Québec. This aligns with FTQ's strategy of combining financial returns with societal impact, leveraging its deep expertise in specialty pharmaceuticals.
What we're watching
- Regulatory Approvals
- Whether donidalorsen secures Health Canada approval and its potential market impact.
- Commercial Execution
- How CELYSTRA scales its commercial operations to address underserved patient populations in Canada.
- Portfolio Expansion
- The pace at which CELYSTRA acquires additional treatments for rare diseases.
Related topics